Encapsulation of propolis extracts in aqueous formulations by using nanovesicles of lipid and poly(styrene-alt-maleic acid)
Source abstract
Abstract
Bee propolis has been used in alternative medicine to treat various diseases. Due to its limited water solubility, it is often used in combination with alcohol solvents, causing skin irritation and immune response. To solve this, the new drug delivery system, based on the lipid nanodiscs of 1,2-dimyristoyl-sn-glycero-3-phosphochline (DMPC) and poly(styrene-alt-maleic acid) (PSMA), were created in an aqueous media. At the excess polymer concentrations, the PSMA/DMPC complexation produced the very fine nanoparticles (18 nm). With the increased molar ratio of styrene to maleic acid (St/MA) in the copolymer structure, the lipid nanodisc showed the improved encapsulation efficiency (EE%), comparing to their corresponding aqueous formulations. The maximum value had reached to around 20% when using the 2:1 PSMA precursor. Based on the cytotoxicity test, these nanoparticles were considered to be non-toxic over the low dose administration region (<78 µg/mL). Instead, they possessed the ability to promote the Vero cell growth. The new PSMA/DMPC nanovesicles could thus be used to improve aqueous solubility and therapeutic effects of poorly water-soluble drugs, thus extending their use in modern therapies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bee Products Chemical Analysis · Essential Oils and Antimicrobial Activity · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Science, Mae Fah Luang University, Chiangrai, Thailand
Aston Institute of Material Research, Aston University, Birmingham, UK
Polymer Research Group, Department of Chemistry, Materials Science Research Center, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand
Funding
National Research Council of Thailand · European Union’s Horizon · research and innovation programme · Marie Sklodowska-Curie
References (51)
Show source-provided references
1. Wagh VD. · Adv Pharmacol Pharm Sci · 2013 · 2013 · 1
2. Daleprane JB · Evid Based Complement Alternat Med · 2013 · 2013 · 17513510.1155/2013/175135 ↗
3. 10.1177/01410768900830031010.1177/014107689008300310 ↗
4. 10.1155/2018/707420910.1155/2018/7074209 ↗
5. 10.1155/2013/97641510.1155/2013/976415 ↗
6. 10.1111/jfbc.1216010.1111/jfbc.12160 ↗
7. 10.1051/apido:1987040410.1051/apido:19870404 ↗
8. 10.3390/scipharm8703002310.3390/scipharm87030023 ↗
9. 10.1186/s12906-018-2234-510.1186/s12906-018-2234-5 ↗
10. Agnihotri N · Indo Global J Pharm Sci · 2012 · 02 · 0110.35652/IGJPS.2012.01 ↗
11. 10.1016/j.colsurfb.2017.07.02910.1016/j.colsurfb.2017.07.029 ↗
12. Saez-Martinez V · React Funct Polym · 2015 · 94 · 910.1016/j.reactfunctpolym.2015.06.015 ↗
13. 10.1016/j.snb.2013.07.02810.1016/j.snb.2013.07.028 ↗
14. Khaojanta T · Polym Eng Sci · 2022 · 62 · 203110.1002/pen.25986 ↗
15. Zareh EN · J Appl Polym Sci · 2011 · 122 · 9710.1002/app.33851 ↗
16. Punyamoonwongsa P · Key Eng Mater · 2019 · 798 · 35110.4028/www.scientific.net/KEM.798.351 ↗
17. Scheidelaar S · Biophys J · 2016 · 111 · 197410.1016/j.bpj.2016.09.025 ↗
18. Tonge S · Adv Drug Deliv Rev · 2001 · 53 · 10910.1016/S0169-409X(01)00223-X ↗
19. Ravula T · Angew Chem Int Ed Engl · 2017 · 56 · 1146610.1002/anie.201705569 ↗
20. Pierre MBR · Braz J Pharm Sci · 2001 · 37 · 355
21. 10.1016/0169-409X(95)00019-410.1016/0169-409X(95)00019-4 ↗
22. 10.1515/epoly-2022-006110.1515/epoly-2022-0061 ↗
23. 10.1007/s00403-011-1166-410.1007/s00403-011-1166-4 ↗
24. Punyamoonwongsa P. Synthetic analogues of protein-lipid complexes [PhD]. Aston University, Birmingham, United Kingdom; 2007.
25. Punyamoonwongsa P · KMUTNB: IJAST · 2018 · 45
26. Magalhães LM · Food Anal Methods · 2012 · 5 · 53010.1007/s12161-011-9278-1 ↗
27. Pujirahayu N · Int J Pharm Pharm Sci · 2014 · 6 · 338
28. 10.1016/j.ejmech.2015.06.02610.1016/j.ejmech.2015.06.026 ↗
29. 10.15282/ijets.v6i2.257710.15282/ijets.v6i2.2577 ↗
30. 10.1590/S0103-5053200400060002610.1590/S0103-50532004000600026 ↗
31. Zin NBM · Int J Eng Technol · 2018 · 7 · 90
32. Lavinas FC · Braz J Pharmacogn · 2019 · 29 · 38910.1016/j.bjp.2018.11.007 ↗
33. Murnen HK · Macromolecules · 2012 · 45 · 522910.1021/ma300707t ↗
34. Zhang R · Chem Phys Lipids · 2017 · 203 · 1910.1016/j.chemphyslip.2016.12.003 ↗
35. Knowles TJ · J Am Chem Soc · 2009 · 131 · 748410.1021/ja810046q ↗
36. Tanaka M · Langmuir · 2015 · 31 · 1271910.1021/acs.langmuir.5b03438 ↗
37. Bjørnestad VA · Langmuir · 2021 · 37 · 617810.1021/acs.langmuir.1c00304 ↗
38. Hall SC · Biomacromolecules · 2018 · 19 · 76110.1021/acs.biomac.7b01539 ↗
39. 10.1038/s41598-018-35262-110.1038/s41598-018-35262-1 ↗
40. Pardo JD · Chem Phys Lipids · 2017 · 208 · 5810.1016/j.chemphyslip.2017.08.010 ↗
41. Stepien P · Biochim Biophys Acta Biomembr · 2020 · 1862 · 18342010.1016/j.bbamem.2020.183420 ↗
42. Stepien P · Biochim Biophys Acta · 2015 · 1848 · 6010.1016/j.bbamem.2014.10.004 ↗
43. Ahangari Z · Iran Endod J · 2018 · 13 · 285
44. 10.1016/j.sjbs.2018.08.01310.1016/j.sjbs.2018.08.013 ↗
45. Rajablou K · Nanomed Res J · 2023 · 8 · 37
46. To CZ · Front Microbiol · 2019 · 10 · 94910.3389/fmicb.2019.00949 ↗
47. 10.1146/annurev.bb.07.060178.00225110.1146/annurev.bb.07.060178.002251 ↗
48. 10.1016/j.mtcomm.2020.10169210.1016/j.mtcomm.2020.101692 ↗
49. Matson ML. · 2012
50. 10.1021/acs.bioconjchem.7b0025210.1021/acs.bioconjchem.7b00252 ↗
51. 10.3390/biomedicines1101021710.3390/biomedicines11010217 ↗